ネクセラファーマ株式会社 · NXERA PHARMA CO., LTD.
Last · Tokyo¥1213.00+30.00 (+2.54%)live · yahoo · 54m ago
Market cap¥110.8B91.4M sh
P/E · TTM-14.2fwd 27.1 · eps -88.12 · loss
Beta0.24vs S&P 500
Div yield0.00%annual · TTM
52w range
¥723.00¥1319.00
Volume717.8Ksession
| Revenue | ¥29.6B |
|---|---|
| Operating income | ¥-8.5B |
| Net income | ¥-12.5B |
| Free cash flow | ¥-4.0B |
| Operating margin | -28.6% |
| Net margin | -42.3% |
| Return on equity | -20.5% |
| Period | 2025 |
Loading chart…
OpenFilings analyst
Our analyst
From latest ANNUAL · 2026-03-25
- Operating Cf Burn
- Net Margin Sharply Negative
- Rd Intensity High
Red flags
- Operating Cf Burn — Negative operating cash flow
- Net Margin Sharply Negative — Net margin -42.3%
- Rd Intensity High — R&D/Revenue 48.8%
Upcoming earnings
7:30 AM UTC+1
Period
Sep 2026
Est. EPS
$0.50
Est. revenue
7.6B
Earnings transcripts
Press & signals
- GlobeNewswire
Nxera Announces Successful Resolution of miniG Patent Infringement Action
- GlobeNewswire
Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress
- GlobeNewswire
Nxera Pharma’s Partner Neurocrine Biosciences Receives IND Acceptance from the FDA for Phase 2 Study of NBI-1117567 for Alzheimer's Cognition
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags